全文获取类型
收费全文 | 10119865篇 |
免费 | 671155篇 |
国内免费 | 155624篇 |
学科分类
医药卫生 | 10946644篇 |
出版年
2022年 | 80692篇 |
2021年 | 181009篇 |
2020年 | 141669篇 |
2019年 | 145509篇 |
2018年 | 177942篇 |
2017年 | 158516篇 |
2016年 | 152679篇 |
2015年 | 189661篇 |
2014年 | 278177篇 |
2013年 | 371548篇 |
2012年 | 523628篇 |
2011年 | 568477篇 |
2010年 | 385015篇 |
2009年 | 346265篇 |
2008年 | 484361篇 |
2007年 | 504924篇 |
2006年 | 482908篇 |
2005年 | 444674篇 |
2004年 | 391774篇 |
2003年 | 363084篇 |
2002年 | 334085篇 |
2001年 | 316872篇 |
2000年 | 315231篇 |
1999年 | 268033篇 |
1998年 | 105197篇 |
1997年 | 91791篇 |
1996年 | 86088篇 |
1995年 | 85128篇 |
1994年 | 77394篇 |
1993年 | 66271篇 |
1992年 | 187036篇 |
1991年 | 181474篇 |
1990年 | 176054篇 |
1989年 | 170850篇 |
1988年 | 157882篇 |
1987年 | 153964篇 |
1986年 | 146786篇 |
1985年 | 140287篇 |
1984年 | 106853篇 |
1983年 | 91780篇 |
1982年 | 58308篇 |
1979年 | 96365篇 |
1978年 | 69246篇 |
1977年 | 59708篇 |
1976年 | 55512篇 |
1975年 | 60602篇 |
1974年 | 70401篇 |
1973年 | 67364篇 |
1972年 | 62454篇 |
1971年 | 57907篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
61.
62.
63.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
64.
Rozhkov V. P. Trifonov M. I. Soroko S. I. 《Neuroscience and behavioral physiology》2022,52(3):383-394
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia... 相似文献
65.
66.
Wan-Jun Zhang Li-Qiang Wu Jun Wang Sheng-Yun Lin Bo Wang 《World Journal of Clinical Cases》2022,10(23):8242-8248
ABSTRACT
BACKGROUND
Hepatitis-associated aplastic anemia (HAAA) is a rare condition. Patients with HAAA usually present with acute hepatitis, jaundice and significantly increased transaminase. After 1–2 mo, hepatitis gradually improves, but progressive hemocytopenia, bone marrow hematopoietic failure, and severe or extremely severe aplastic anemia are manifest. Most cases of HAAA are fulminant and usually lethal if left untreated. The literature on Epstein–Barr virus (EBV)-associated HAAA is sparse.
CASE SUMMARY
We report a 30-year-old man who was admitted to our hospital because of pale yellow urine and skin with a simultaneous decrease in peripheral blood ternary cells. We made a diagnosis of EBV-associated HAAA. The treatment strategy for this patient included eltrombopag, an immunosuppressive regimen of rabbit anti-human thymocyte immunoglobulin, cyclosporine, and supportive care. The patient was discharged in normal physical condition after five months. A hemogram performed on follow-up revealed that he had achieved a complete response.
CONCLUSION
Eltrombopag plus anti-thymocyte globubin and cyclosporine may be a therapeutic option for EBV-associated HAAA.Larger studies are warranted to confirm. 相似文献
67.
68.
69.
70.